Drug Trial Radar · NCT07020117
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Aug 22, 2025
Primary completion
Dec 2027
Study completion Jun 2032
Sponsor
- Lead sponsor
- Aktis Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.
Conditions
- Urothelial Carcinoma Bladder
- Triple Negative Breast Cancer (TNBC)
- Hormone Receptor Positive Breast Adenocarcinoma
- Non Small Cell Lung Cancer
- Cervical Adenocarcinoma
- Colorectal Adenocarcinoma
- Head and Neck Cancer
Interventions
[225Ac]Ac-AKY-1189 (therapeutic)Drug
\[225Ac\]Ac-AKY-1189 Injection
[64Cu]Cu-AKY-1189 (imaging)Drug
\[64Cu\]Cu-AKY-1189 Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Patients with Dose-Limiting ToxicitiesTime frame: From enrollment to the end of Cycle 1 (each cycle is 28 days)
- Part 1: Occurence of Adverse Events by SeverityTime frame: Up to the End of Treatment (30 days after the last dose)
- Part 2: Objective Response Rate (ORR)Time frame: Up to 30 days following last administration
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
Hoag Memorial Hospital Presbyterian
Irvine, California · Recruiting
Biogenix Molecular, LLC
Miami, Florida · Withdrawn
Advent Health Medical Group Radiation Oncology at Central Florida
Orlando, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
University of Kansas
Westwood, Kansas · Recruiting
United Theranostics
Glen Burnie, Maryland · Recruiting
BAMF Health
Grand Rapids, Michigan · Recruiting
Icahn School of Medicine at Mt. Sinai
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
UPMC
Pittsburgh, Pennsylvania · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.